Traws Pharma, Inc. (NASDAQ:TRAW) Receives Consensus Rating of “Hold” from Brokerages

Shares of Traws Pharma, Inc. (NASDAQ:TRAW) have been given a consensus recommendation of “Hold” by the five ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, one has given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $8.00.

Several research analysts have recently issued reports on TRAW shares. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Traws Pharma in a research note on Wednesday, May 20th. Weiss Ratings downgraded shares of Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a research report on Friday, May 29th. Citigroup downgraded shares of Traws Pharma to a “neutral” rating in a research report on Monday. Finally, Wall Street Zen upgraded shares of Traws Pharma from a “strong sell” rating to a “sell” rating in a research report on Saturday.

Insiders Place Their Bets

In related news, major shareholder Orbimed Advisors Llc acquired 597,729 shares of the stock in a transaction that occurred on Thursday, April 16th. The shares were bought at an average price of $1.67 per share, for a total transaction of $998,207.43. Following the completion of the transaction, the insider directly owned 1,203,250 shares in the company, valued at approximately $2,009,427.50. This trade represents a 98.71% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.57% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Traws Pharma

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Two Sigma Investments LP raised its holdings in Traws Pharma by 37.1% in the 3rd quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock worth $41,000 after purchasing an additional 5,955 shares during the period. Geode Capital Management LLC raised its holdings in Traws Pharma by 41.9% in the 4th quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock worth $70,000 after purchasing an additional 18,213 shares during the period. State Street Corp bought a new position in Traws Pharma in the 4th quarter worth $29,000. Adage Capital Partners GP L.L.C. raised its holdings in Traws Pharma by 121.2% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 730,000 shares of the company’s stock worth $825,000 after purchasing an additional 400,000 shares during the period. Finally, ADAR1 Capital Management LLC bought a new position in Traws Pharma in the 4th quarter worth $175,000. 7.95% of the stock is currently owned by hedge funds and other institutional investors.

Traws Pharma Stock Performance

Shares of NASDAQ TRAW opened at $1.28 on Monday. The firm’s 50 day moving average price is $1.49 and its 200-day moving average price is $1.74. The company has a market cap of $13.00 million, a PE ratio of -0.76 and a beta of 1.45. Traws Pharma has a 52-week low of $1.00 and a 52-week high of $3.27.

Traws Pharma (NASDAQ:TRAW) last issued its earnings results on Friday, May 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.39. On average, analysts forecast that Traws Pharma will post -2.23 earnings per share for the current fiscal year.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.